Amundi Buys 15,128 Shares of STAAR Surgical (NASDAQ:STAA)

Amundi grew its stake in STAAR Surgical (NASDAQ:STAA) by 174.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,785 shares of the medical instruments supplier’s stock after purchasing an additional 15,128 shares during the quarter. Amundi’s holdings in STAAR Surgical were worth $550,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. State Street Corp raised its position in shares of STAAR Surgical by 0.5% in the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock valued at $72,092,000 after purchasing an additional 10,430 shares during the period. Geode Capital Management LLC increased its position in STAAR Surgical by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after acquiring an additional 31,212 shares during the period. Defender Capital LLC. increased its position in STAAR Surgical by 3.5% during the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock worth $17,041,000 after acquiring an additional 23,950 shares during the period. American Capital Management Inc. increased its position in STAAR Surgical by 42.9% during the third quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier’s stock worth $19,051,000 after acquiring an additional 154,037 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in STAAR Surgical by 4.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 444,290 shares of the medical instruments supplier’s stock worth $10,792,000 after acquiring an additional 18,168 shares during the period. 96.70% of the stock is owned by institutional investors.

STAAR Surgical Price Performance

STAA opened at $17.92 on Friday. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $52.68. The firm has a market capitalization of $883.90 million, a price-to-earnings ratio of -43.71 and a beta of 0.66. The company’s 50 day moving average price is $19.97 and its two-hundred day moving average price is $25.81.

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock in a transaction on Thursday, March 20th. The shares were purchased at an average cost of $17.96 per share, with a total value of $1,952,611.20. Following the acquisition, the insider now directly owns 12,182,995 shares of the company’s stock, valued at $218,806,590.20. The trade was a 0.90 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired 1,036,187 shares of company stock valued at $17,239,548 in the last ninety days. 1.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

STAA has been the topic of a number of recent research reports. Jefferies Financial Group lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Stifel Nicolaus decreased their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. StockNews.com lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. BTIG Research lowered shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Finally, Piper Sandler decreased their target price on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, STAAR Surgical currently has an average rating of “Hold” and a consensus target price of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.